Unknown

Dataset Information

0

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-? Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.

ABSTRACT: Optimization of isoquinolinone PI3K inhibitors led to the discovery of a potent inhibitor of PI3K-? (26 or IPI-549) with >100-fold selectivity over other lipid and protein kinases. IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-? mediated neutrophil migration in vivo and is currently in Phase 1 clinical evaluation in subjects with advanced solid tumors.

SUBMITTER: Evans CA 

PROVIDER: S-EPMC5018865 | biostudies-other | 2016 Sep

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Optimization of isoquinolinone PI3K inhibitors led to the discovery of a potent inhibitor of PI3K-γ (26 or IPI-549) with >100-fold selectivity over other lipid and protein kinases. IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-γ mediated neutrophil migration in vivo and is currently in Phase 1 clinical evaluation in subjects with advanced solid tumors. ...[more]

Similar Datasets

Unknown Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGF?R1 Inhibitor as an Immuno-oncology Agent.
| S-EPMC7025382 | biostudies-literature
Unknown The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
| S-EPMC4558374 | biostudies-literature
Unknown Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.
| S-EPMC4834666 | biostudies-literature
Unknown INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
| S-EPMC5430407 | biostudies-literature
Unknown Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
| S-EPMC3510823 | biostudies-literature
Unknown Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
| S-EPMC7549094 | biostudies-literature
Transcriptomics AVA-ADR-001- a small molecular inhibitor of ADAR1 (Immuno-oncology target)
2023-04-17 | GSE229503 | GEO
Unknown Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
| S-EPMC5735832 | biostudies-literature
Unknown Discovery of 4-Azaindole Inhibitors of TGF?RI as Immuno-oncology Agents.
| S-EPMC6231184 | biostudies-literature
Unknown Personalized Immuno-Oncology.
| S-EPMC7923844 | biostudies-literature